MY177028A - Solid compositions of triglycerides and uses thereof - Google Patents
Solid compositions of triglycerides and uses thereofInfo
- Publication number
- MY177028A MY177028A MYPI2016000861A MYPI2016000861A MY177028A MY 177028 A MY177028 A MY 177028A MY PI2016000861 A MYPI2016000861 A MY PI2016000861A MY PI2016000861 A MYPI2016000861 A MY PI2016000861A MY 177028 A MY177028 A MY 177028A
- Authority
- MY
- Malaysia
- Prior art keywords
- solid compositions
- triglycerides
- triheptanoin
- spray
- drying
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The present invention includes solid compositions of triglycerides with one or more fatty acids, such as triheptanoin and glycerol phenylbutyrate, and therapeutic use thereof. The solid compositions can be prepared by spray-drying or other processes. Figure 1
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361904369P | 2013-11-14 | 2013-11-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
MY177028A true MY177028A (en) | 2020-09-02 |
Family
ID=53058066
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MYPI2016000861A MY177028A (en) | 2013-11-14 | 2014-11-14 | Solid compositions of triglycerides and uses thereof |
Country Status (18)
Country | Link |
---|---|
US (3) | US20160243071A1 (en) |
EP (2) | EP3068383B1 (en) |
JP (3) | JP2017501972A (en) |
KR (1) | KR102291310B1 (en) |
CN (2) | CN113181158A (en) |
AR (1) | AR099353A1 (en) |
AU (1) | AU2014348470B2 (en) |
CA (2) | CA2929688C (en) |
CL (1) | CL2016001130A1 (en) |
ES (1) | ES2833294T3 (en) |
IL (1) | IL245588B (en) |
MX (2) | MX2016006329A (en) |
MY (1) | MY177028A (en) |
PE (1) | PE20161024A1 (en) |
PH (1) | PH12016500821A1 (en) |
RU (1) | RU2016123169A (en) |
TW (1) | TWI640327B (en) |
WO (1) | WO2015073816A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020041871A1 (en) * | 2018-08-27 | 2020-03-05 | Exerkine Corporation | Method for treating lysosomal storage disease |
US11583542B2 (en) * | 2019-12-16 | 2023-02-21 | Amylyx Pharmaceuticals, Inc. | Compositions of bile acids and phenylbutyrate compounds |
CN113476408A (en) * | 2021-07-23 | 2021-10-08 | 兆科药业(广州)有限公司 | Phenylbutyrin granules and preparation method and application thereof |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2800610B2 (en) * | 1992-12-15 | 1998-09-21 | 不二製油株式会社 | Production method of oil-in-water emulsion |
JP3522843B2 (en) * | 1994-07-29 | 2004-04-26 | 昭和産業株式会社 | Lipo preparation |
CA2212047C (en) | 1995-02-07 | 2010-11-16 | Saul W. Brusilow | Triglycerides and ethyl esters of phenylalkanoic acid and phenylalkenoic acid useful in treatment of various disorders |
JPH08311480A (en) * | 1995-05-18 | 1996-11-26 | D H Ee Kodo Seisei Chushutsu Gijutsu Kenkyu Kumiai | Production of oil or fat comprising high-purify triacylglycerol and oil or fat composition containing highly unsaturated fatty acid |
CN101574335A (en) * | 1999-02-05 | 2009-11-11 | 贝勒研究院 | Nutritional supplement or pharmaceutical preparation comprising triglycerides with seven carbon fatty acid |
WO2004103307A2 (en) * | 2003-05-20 | 2004-12-02 | Baylor Research Institute | Method of use of five and fifteen carbon fatty acids |
US20050058673A1 (en) * | 2003-09-09 | 2005-03-17 | 3M Innovative Properties Company | Antimicrobial compositions and methods |
US7141114B2 (en) * | 2004-06-30 | 2006-11-28 | Rec Silicon Inc | Process for producing a crystalline silicon ingot |
EP1773317A4 (en) * | 2004-07-02 | 2012-10-03 | Baylor Res Inst | Glycogen or polysaccharide storage disease treatment method |
TW200719884A (en) * | 2005-03-10 | 2007-06-01 | 3M Innovative Properties Co | Methods of treating ear infections |
WO2006099358A2 (en) * | 2005-03-10 | 2006-09-21 | 3M Innovative Properties Company | Antimicrobial compositions comprising esters of hydroxycarboxylic acids |
CA2641852A1 (en) * | 2006-02-10 | 2007-08-16 | Sportscom Danmark Aps | Coated tablets, their methods of preparation, and related uses |
JP5296366B2 (en) * | 2007-10-29 | 2013-09-25 | 日清オイリオグループ株式会社 | Endurance improver for drugs and endurance drug |
PL3133396T3 (en) | 2008-04-29 | 2019-03-29 | Horizon Therapeutics, Llc | Methods of treatment using ammonia-scavenging drugs |
MX2012014520A (en) * | 2010-06-14 | 2013-03-05 | Baylor Res Inst | Triheptanoin diet for adult polyglucosan body disease (apbd) treatment. |
CN101919453B (en) * | 2010-08-16 | 2013-04-10 | 苏州市佳禾食品工业有限公司 | Medium carbon chain fatty acid powder grease and preparation method thereof |
RS56196B1 (en) | 2011-09-30 | 2017-11-30 | Horizon Therapeutics Llc | Nitrogen scavenging drug for use in a method of treating a nitrogen retention disorder |
TWI572352B (en) * | 2012-03-01 | 2017-03-01 | 波麥堤克藥學Smt有限公司 | Method for the preparation of triglycerides of medium-chain length fatty acids |
EP2838522B1 (en) * | 2012-04-16 | 2024-02-21 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Phenylbutyrate for the treatment of medium-chain acyl-coa dehydrogenase deficiency |
CA2894456C (en) | 2012-12-13 | 2022-06-28 | Baylor Research Institute | Triheptanoin for the treatment of glucose transporter 1 deficiency |
-
2014
- 2014-11-14 WO PCT/US2014/065693 patent/WO2015073816A1/en active Application Filing
- 2014-11-14 PE PE2016000621A patent/PE20161024A1/en not_active Application Discontinuation
- 2014-11-14 CN CN202110316004.0A patent/CN113181158A/en active Pending
- 2014-11-14 CN CN201480064471.7A patent/CN105764497A/en active Pending
- 2014-11-14 TW TW103139665A patent/TWI640327B/en active
- 2014-11-14 US US14/419,601 patent/US20160243071A1/en not_active Abandoned
- 2014-11-14 JP JP2016529444A patent/JP2017501972A/en active Pending
- 2014-11-14 ES ES14861440T patent/ES2833294T3/en active Active
- 2014-11-14 CA CA2929688A patent/CA2929688C/en active Active
- 2014-11-14 MX MX2016006329A patent/MX2016006329A/en unknown
- 2014-11-14 AU AU2014348470A patent/AU2014348470B2/en active Active
- 2014-11-14 AR ARP140104294A patent/AR099353A1/en not_active Application Discontinuation
- 2014-11-14 EP EP14861440.7A patent/EP3068383B1/en active Active
- 2014-11-14 EP EP20196269.3A patent/EP3782610A1/en active Pending
- 2014-11-14 CA CA3197154A patent/CA3197154A1/en active Pending
- 2014-11-14 KR KR1020167013964A patent/KR102291310B1/en active IP Right Grant
- 2014-11-14 RU RU2016123169A patent/RU2016123169A/en unknown
- 2014-11-14 MY MYPI2016000861A patent/MY177028A/en unknown
-
2016
- 2016-05-03 PH PH12016500821A patent/PH12016500821A1/en unknown
- 2016-05-10 IL IL245588A patent/IL245588B/en unknown
- 2016-05-11 CL CL2016001130A patent/CL2016001130A1/en unknown
- 2016-05-13 MX MX2021001790A patent/MX2021001790A/en unknown
-
2019
- 2019-06-19 US US16/445,557 patent/US20200069631A1/en not_active Abandoned
-
2020
- 2020-03-11 JP JP2020041943A patent/JP2020111585A/en active Pending
-
2022
- 2022-05-16 JP JP2022080251A patent/JP2022107017A/en active Pending
-
2023
- 2023-02-10 US US18/167,551 patent/US20230181513A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
RU2016123169A (en) | 2017-12-19 |
AU2014348470B2 (en) | 2020-01-30 |
IL245588A0 (en) | 2016-06-30 |
ES2833294T3 (en) | 2021-06-14 |
IL245588B (en) | 2021-08-31 |
US20160243071A1 (en) | 2016-08-25 |
EP3068383B1 (en) | 2020-09-16 |
TWI640327B (en) | 2018-11-11 |
US20200069631A1 (en) | 2020-03-05 |
MX2016006329A (en) | 2016-09-06 |
PH12016500821A1 (en) | 2016-06-13 |
EP3068383A4 (en) | 2017-11-08 |
MX2021001790A (en) | 2021-04-19 |
PE20161024A1 (en) | 2016-11-10 |
JP2017501972A (en) | 2017-01-19 |
JP2020111585A (en) | 2020-07-27 |
CN105764497A (en) | 2016-07-13 |
US20230181513A1 (en) | 2023-06-15 |
EP3782610A1 (en) | 2021-02-24 |
AU2014348470A1 (en) | 2016-05-26 |
AR099353A1 (en) | 2016-07-20 |
CL2016001130A1 (en) | 2017-01-20 |
TW201609189A (en) | 2016-03-16 |
WO2015073816A1 (en) | 2015-05-21 |
CA2929688C (en) | 2023-06-13 |
KR102291310B1 (en) | 2021-08-23 |
JP2022107017A (en) | 2022-07-20 |
KR20160084407A (en) | 2016-07-13 |
CA3197154A1 (en) | 2015-05-21 |
EP3068383A1 (en) | 2016-09-21 |
CN113181158A (en) | 2021-07-30 |
CA2929688A1 (en) | 2015-05-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12016500587B1 (en) | Octanoic, nonanoic and decanoic fatty acids with a pyrethroid adulticide | |
MX2019015311A (en) | Cannabidiolic acid esters compositions and uses thereof. | |
WO2014057362A3 (en) | Omega -3 compositions | |
MX362349B (en) | Minoxidil-containing hair growth composition. | |
EP3878445A3 (en) | Acamprosate formulations, methods of using the same, and combinations comprising the same | |
SG10201907875TA (en) | Modified meningococcal fhbp polypeptides | |
IN2014DN07483A (en) | ||
SA515361092B1 (en) | Racecadotril lipid compositions | |
EP3074000A4 (en) | Suspension compositions of physiologically active phenolic compounds&methods of making and using the same | |
EP3068500A4 (en) | Fertilizer compositions and methods of making and using the same | |
WO2015092810A3 (en) | Amorphous form of idelalisib | |
IN2014DN11078A (en) | ||
MX2017008450A (en) | Microencapsulated nitrification inhibitor compositions. | |
EP3232770A4 (en) | Generation of transgenic canola with low or no saturated fatty acids | |
EP3445849A4 (en) | Methods and compositions to enhance the anti-inflammatory effects of interleukin 10 | |
MX369223B (en) | Sunscreen compositions. | |
MX2018002514A (en) | Modified cytotoxins and their therapeutic use. | |
WO2014165190A3 (en) | Compositions comprising docosapentaenoic acid and methods of use | |
MX2021001790A (en) | Solid compositions of triglycerides and uses thereof. | |
MY178960A (en) | Hiv treatment formulation of atazanavir and cobicistat | |
WO2014133811A3 (en) | Compounds from invasive salvinias and methods of using the same | |
MX2015016410A (en) | Esters of oligo-hydroxycarboxylic acids and use thereof. | |
IN2014DN06617A (en) | ||
BR112016028561A8 (en) | composition and dosage form comprising a marine oil comprising fatty acids, and use thereof | |
EP3027180A4 (en) | Compositions and methods of the treatment of fatty acid metabolism disorders |